Haumann's extensive biotech and pharmaceutical leadership experience includes more than 20 years of development and discovery work in allergy and pulmonary medicines.
Haumann is chief medical officer and senior vice president, clinical development, at Theravance Biopharma.
Prior to joining Theravance Inc. in 2013, Haumann served as chief medical officer of the UK allergy company Circassia Ltd.
He also spent more than a decade with GlaxoSmithKline, where, as vice president of clinical development, he was responsible for late-stage development of medicines for asthma and chronic obstructive pulmonary disease.
Haumann began his industry career with Glaxo Wellcome in the United Kingdom and South Africa, after working as an internal medicine practitioner and clinical researcher in South Africa.
Aimmune Therapeutics is a biopharmaceutical company developing treatments for life-threatening food allergies.
The company's Characterized Oral Desensitization ImmunoTherapy (CODIT) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens.
Aimmune's first investigational biologic product using CODIT, AR101 for the treatment of peanut allergy, has received the FDA's Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4–17 years of age.
The company plans to submit regulatory filings for marketing approval of AR101 in the United States and Europe based on data from the pivotal Phase 3 PALISADE clinical trial of AR101, which in 4–17-year-old subjects met its primary and key secondary endpoints, and additional ongoing and completed AR101 clinical trials.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business